Creating waves with PALYNZIQ® ▼ (pegvaliase): Three years of experience in Europe
Chair: Cary Harding, Portland, United States

Welcome & introduction: PALYNZIQ® three years on
Cary Harding, Portland, United States

Riding the waves of change: My experience with PALYNZIQ®
Valentina Rovelli, Milan, Italy

My journey with PALYNZIQ®: A smooth sea does not make a skilled sailor
Ania Muntau, Hamburg, Germany

Q&A
Cary Harding, Portland, United States

sponsored by

▲This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Healthcare professionals should report adverse events in accordance with their local requirements. Adverse events should also be reported to BioMarin on +1 415 506 6179 or drugsafety@bmrn.com.

Other disclaimers:
PALYNZIQ® is indicated for the treatment of patients with PKU aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 µmol/L) despite prior management with available treatment options.

This symposium has been initiated, organised and funded by BioMarin. This symposium is intended for healthcare professionals registered for SSIEM 2022. Prescribing information can be found at the BioMarin booth.